Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

ConditionHealthy Volunteers

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age19+

SponsorDaewoong Pharmaceutical Co. LTD.

About this trial

This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.

Eligibility criteria

Qualifiers

Over 19 year old

Healthy adult volunteers

Disqualifiers

with a history of mental disorder

For female volunteers, those who are suspected of being pregnant or lactating

Trial design

Treatments tested in this trial

DWJ1622
DWC202313, DWC202314

Treatment groups

36 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Daewoong Pharmaceutical Co. LTD.

Lead sponsor

Source ClinicalTrials.gov